Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Older adults less likely to be tested for influenza

29 Jan 2018

Elderly adults hospitalized for fever or respiratory syndromes are much less likely than younger adults to be recommended for influenza testing, a recent study has shown. This is partly explained by a lower likelihood to present with influenza-like illnesses (ILI).

The study included 1,422 adults hospitalized for symptoms of acute respiratory illness or nonlocalizing fever. Wilcoxon test and Person’s chi-square test were used to compare characteristics between those who were (28 percent; n=399) and were not recommended for influenza testing.

Compared with young adults, elderly adults were much less likely to receive influenza testing. For instance, the mean age of those who were ordered for testing was significantly lower than those who were not (58±18 vs 66±15 years; p<0.001).

Those presenting with ILI were also more likely to receive testing. Age also played a significant role in this subgroup, such that the ILI patients who underwent influenza testing were significantly younger than those who did not (55±10 vs 63±9 years; p=0.027).

In a multivariable logistic regression model, younger age was found to be a significant predictor of influenza testing in hospitalized patients with acute respiratory illness (adjusted odds ratio [OR], 2.02; 95 percent CI, 1.55–2.63).

Other significant predictors include no history of lung disease (adjusted OR, 1.68; 1.26–2.24) and ILI symptoms (adjusted OR, 2.22; 1.71–2.89).

“Despite being at high risk for morbidity and mortality from influenza virus infection and sequelae, hospitalized older adults were tested for influenza less often than their younger counterparts,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.